sporanox 100 mg trde kapsule
johnson & johnson d.o.o. - itrakonazol - kapsula, trda - itrakonazol 100 mg / 1 kapsula - itrakonazol
euvascor 10 mg/10 mg trde kapsule
atorvastatin - kapsula, trda - atorvastatin 10 mg / 1 kapsula - atorvastatin in perindopril
euvascor 40 mg/5 mg trde kapsule
perindopril; perindopril - kapsula, trda - perindopril 3,395 mg / 1 kapsula perindopril3,395 mg / 1 kapsula; perindopril 3,395 mg / 1 kapsula - atorvastatin in perindopril
lusmose 50 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 50 mg / 1 kapsula - sunitinib
sunitinib krka 12,5 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 12,5 mg / 1 kapsula - sunitinib
sunitinib krka 25 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 25 mg / 1 kapsula - sunitinib
sunitinib krka 50 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 50 mg / 1 kapsula - sunitinib
rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastična sredstva - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.
emend
merck sharp & dohme b.v. - aprepitant - vomiting; postoperative nausea and vomiting; cancer - antiemetics in antinauseants, - emend 40 mg trde kapsule je indicirano za preprečevanje pooperativne navzee in bruhanja (ponv) pri odraslih. emend je na voljo tudi kot 80 mg in 125 mg trde kapsule za preprečevanje slabosti in bruhanja, povezanih z močno in zmerno emetogenic kemoterapijo raka pri odraslih in mladostnikih v starosti od 12 (glej ločen povzetek glavnih značilnosti zdravila). emend je na voljo tudi kot 165 mg trde kapsule za preprečevanje akutne in zapoznele slabost in bruhanja, povezanih z močno emetogenic cisplatin, ki temelji kemoterapijo raka pri odraslih in preprečevanje slabosti in bruhanja, povezanih z zmerno emetogenic kemoterapijo raka pri odraslih. emend je na voljo tudi v obliki praška za ustno suspenzije za preprečevanje slabosti in bruhanja, povezanih z močno in zmerno emetogenic kemoterapijo raka pri otrocih, malčke in dojenčke, starejše od 6 mesecev do manj kot 12 let. emend 80 mg, 125 mg, 165 mg trde kapsule in emend v prahu za ustno vzmetenje so podana kot del kombiniranega zdravljenja.
teysuno
nordic group b.v. - tegafur, gimeracil, oteracil - Želodne neoplazme - antineoplastična sredstva - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.